Similar effects have been reported in RCC through targeting SLC2A1/GLUT1 (Yamasaki et al., 2013) which it has also been reported to be overexpressed in human breast carcinomas (da Cunha et al., 2013), in esophageal carcinomas by inhibiting mucin 1 (MUC1) (Luo et al., 2015), whereas miR-1291 acts upstream of the Rho GTPase-activating protein 29 (ArhGAP29) to negatively regulate the RhoA/ROCK1 epithelial mesenchymal transition (EMT) pathway, ultimately leading to endometrial fibrosis (Xu et al., 2017). The gene discussed is SLC2A1; the disease is renal cell carcinoma.